Novo Nordisk | NVO - Current Assets


Novo Nordisk reported DKK25.71B in Current Assets for its fiscal quarter ending in June of 2025.





Current Assets Change Date
ANI Pharmaceuticals USD 747.08M 6.03M Mar/2026
Aurora Cannabis CAD 445.84M 22M Dec/2025
Bausch Health Companies USD 5.98B 179M Mar/2026
Bristol-Myers Squibb USD 27.21B 2.18B Mar/2026
Canopy Growth CAD 524.67M 78.85M Dec/2025
Corcept Therapeutics USD 426.03M 59.43M Mar/2026
Drreddys Laboratories INR 3.31B 164.26M Dec/2025
Eli Lilly USD 54.84B 794M Mar/2026
GlaxoSmithKline GBP 17.76B 251M Mar/2026
Merck USD 35.02B 8.5B Mar/2026
Nektar Therapeutics USD 266.27M 15.09M Dec/2025
Novartis USD 26.61B 3.85B Mar/2026
Novo Nordisk DKK 177.32B 4.86B Mar/2026
Novo Nordisk DKK 25.71B 148.69B Jun/2025
Pacira USD 514.96M 33.01M Mar/2026
Perrigo USD 2.71B 85M Mar/2026
Phibro Animal Health USD 894.07M 31.88M Mar/2026
Prestige Brands USD 431.48M 1.94M Mar/2026
Sanofi EUR 30.16B 789M Mar/2026
Supernus Pharmaceuticals USD 731.58M 87.4M Mar/2026
Zoetis USD 6.47B 294M Mar/2026